Cipargamin

Novartis 

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Severe malaria treatment
MoA
  • PfATP4 inhibitor
Key features
  • Novel mechanism of action for resistance management
  • Potentially simplified dosing schedule
  • Very rapid killing of parasites
  • Potential for transmission-blocking activity shown in a Standard Membrane Feeding Assay
Status
  • Phase II oral malaria patient study and parenteral GLP safety study completed
  •  First-in-human study with intravenous formulation completed
Next milestone
  • Initiate phase II study in severe malaria patients
Previously
  • Names NITD609, KAE609. Novartis in discovery partnership with MMV,  Wellcome Trust and the Swiss Tropical and Public Health Institute
MMV Project Director
  • Dr Gonzalo Acuña